Mrs Gina S Nelson, MD | |
1297 Burns Way Ste 2, Kalispell, MT 59901-3162 | |
(406) 755-6550 | |
Not Available |
Full Name | Mrs Gina S Nelson |
---|---|
Gender | Female |
Speciality | Obstetrics/gynecology |
Experience | 35 Years |
Location | 1297 Burns Way Ste 2, Kalispell, Montana |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1477683159 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207VX0000X | Obstetrics & Gynecology - Obstetrics | 7570 (Montana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kalispell Regional Medical Center | Kalispell, MT | Hospital |
Mailing Address | Practice Location Address |
---|---|
Mrs Gina S Nelson, MD 1297 Burns Way Ste 2, Kalispell, MT 59901-3162 Ph: (406) 755-6550 | Mrs Gina S Nelson, MD 1297 Burns Way Ste 2, Kalispell, MT 59901-3162 Ph: (406) 755-6550 |
News Archive
YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.
Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.
TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.
Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.
Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).
› Verified 9 days ago
Charles Ludden, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 350 Lake Hills Dr, Kalispell, MT 59901 Phone: 406-212-0184 | |
Jenna R Huff, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 210 Sunnyview Lane, 201, Kalispell, MT 59901 Phone: 406-752-5252 Fax: 406-752-5261 | |
Mr. Richard Harlan Taylor, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 75 Claremont, Kalispell, MT 59901 Phone: 406-752-8282 Fax: 406-257-2225 | |
Dr. Debra Jean Klein, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1297 Burns Way, Kalispell, MT 59901 Phone: 406-752-0303 Fax: 406-752-0314 | |
Erin Caitlin Lauer, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 210 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-752-5252 | |
Perry Keith Birky, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 210 Sunnyview Ln Ste 201, Kalispell, MT 59901 Phone: 406-858-8200 Fax: 406-858-6803 |